- Home
- GLUE
as 07-11-2025 1:34pm EST
Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.
| Founded: | 2019 | Country: | United States |
| Employees: | N/A | City: | BOSTON |
| Market Cap: | 283.6M | IPO Year: | 2021 |
| Target Price: | $13.50 | AVG Volume (30 days): | 415.2K |
| Analyst Decision: | Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.08 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.50 - $12.40 | Next Earning Date: | 08-07-2025 |
| Revenue: | $159,487,000 | Revenue Growth: | 14889.38% |
| Revenue Growth (this year): | 49.02% | Revenue Growth (next year): | -60.26% |
Stock Insider Trading Activity of Monte Rosa Therapeutics Inc. (GLUE)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Dunn Edmund | GLUE | Principal Accounting Officer | Jun 3 '25 | Sell | $4.45 | 2,062 | $9,174.46 | 23,732 |
Latest Monte Rosa Therapeutics Inc. News
GLUE Breaking Stock News: Dive into GLUE Ticker-Specific Updates for Smart Investing
MT Newswires
a month ago
Monte Rosa Therapeutics Says US FDA Accepts Investigational New Drug Application for MRT-8102
GlobeNewswire
a month ago
Monte Rosa Therapeutics Announces FDA Clearance of IND Application for MRT-8102, a NEK7-Directed Molecular Glue Degrader for the Treatment of Multiple Inflammatory Diseases
Zacks
a month ago
Wall Street Analysts Think Monte Rosa Therapeutics (GLUE) Could Surge 222.16%: Read This Before Placing a Bet
GlobeNewswire
a month ago
Monte Rosa Therapeutics to Participate in the Jefferies Global Healthcare Conference
Zacks
2 months ago
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates
Associated Press Finance
2 months ago
Monte Rosa Therapeutics: Q1 Earnings Snapshot
GlobeNewswire
2 months ago
Monte Rosa Therapeutics Announces First Quarter 2025 Financial Results and Business Updates
GlobeNewswire
2 months ago
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
Compare GLUE vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "GLUE Monte Rosa Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.